Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)

Pituitary

Volumn 10, Issue 3, 2007, Pages 261-266

  Manuchehri, Alireza M ^a   Sathyapalan, Thozhukat ^a,d   Lowry, Martin ^a   Turnbull, Lindsay W ^b   Rowland Hill, Christopher ^c   Atkin, Stephen L ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^d Centre for Diabetes and Endocrinology   (United Kingdom)

Author keywords

Dopamine agonist (DA); Dynamic contrast enhanced magnetic resonance imaging (DCE MRI); Prolactinoma

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ORAL CONTRACEPTIVE AGENT; PROLACTIN; QUINAGOLIDE;

ADOLESCENT; ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER INHIBITION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; TREATMENT DURATION; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AMINOQUINOLINES; CONTRACEPTIVES, ORAL, HORMONAL; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY GLAND; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA;

EID: 35848930579     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-007-0048-4     Document Type: Article

References (24)

1. Park SK, Keenan MW, Selmanoff M (1993) Graded hyperprolactinemia first suppresses LH pulse frequency and then pulse amplitude in castrated male rats. Neuroendocrinology 58:448-453
2. Webster J (1999) Clinical management of prolactinomas. Baillieres Best Pract Res Clin Endocrinol Metab 13:395-408
3. Tindall GT, Kovacs K, Horvath E, Thorner MO (1982) Human prolactin-producing adenomas and bromocriptine: A histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 55:1178-1183
4. Rengachary SS, Tomita T, Jefferies BF, Watanabe I (1982) Structural changes in human pituitary tumor after bromocriptine therapy. Neurosurgery 10:242-251
5. Nissim M, Ambrosi B, Bernasconi V et al (1982) Bromocriptine treatment of macroprolactinomas: Studies on the time course of tumor shrinkage and morphology. J Endocrinol Invest 5:409-415
6. Landolt AM, Minder H, Osterwalder V, Landolt TA (1983) Bromocriptine reduces the size of cells in prolactin-secreting pituitary adenomas. Experientia 39:625-626
7. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: From structure to function. Physiol Rev 78:189-225
8. Bevan JS, Webster J, Burke CW, Scanlon MF (1992) Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13:220-240
9. Conner P, Fried G (1998) Hyperprolactinemia; etiology, diagnosis and treatment alternatives. Acta Obstet Gynecol Scand 77:249-262
10. Pellegrini I, Rasolonjanahary R, Gunz G et al (1989) Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69:500-509
11. Caccavelli L, Feron F, Morange I et al (1994) Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 60:314-322
12. Mross K, Fuxius S, Drevs J (2002) Serial measurements of pharmacokinetics, DCE-MRI, blood flow, PET and biomarkers in serum/ plasma - what is a useful tool in clinical studies of anti-angiogenic drugs? Int J Clin Pharmacol Ther 40:573-574
13. Zirrgiebel U, Drevs J (2003) Surrogate marker in clinical studies with anti-angiogenic drugs. Int J Clin Pharmacol Ther 41:600-602
14. Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ (1991) Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 15:621-628
15. Buckley DL, Kerslake RW, Blackband SJ, Horsman A (1994) Quantitative analysis of multi-slice Gd-DTPA enhanced dynamic MR images using an automated simplex minimization procedure. Magn Reson Med 32:646-651
16. Tofts PS (1997) Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7:91-101
17. Hittmair K, Gomiscek G, Langenberger K, Recht M, Imhof H, Kramer J (1994) Method for the quantitative assessment of contrast agent uptake in dynamic contrast-enhanced MRI. Magn Reson Med 31:567-571
18. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA (2000) Angiogenesis in pituitary adenomas and the normal pituitary gland. J Clin Endocrinol Metab 85:1159-1162
19. Dirksen A, Langereis S, de Waal BF et al (2004) Design and synthesis of a bimodal target-specific contrast agent for angiogenesis. Org Lett 6:4857-4860
20. Basu S, Nagy JA, Pal S et al (2001) The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 7:569-574
21. Viacava P, Gasperi M, Acerbi G et al (2003) Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J Endocrinol Invest 26:23-28
22. McCabe CJ, Boelaert K, Tannahill LA et al (2002) Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87:4238-4244
23. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW (1996) Extrapituitary prolactin: Distribution, regulation, functions, and clinical aspects. Endocr Rev 17:639-669
24. Testa G, Vegetti W, Motta T et al (1998) Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 58:69-73